Mayer Davidson to Cost-Benefit Analysis
This is a "connection" page, showing publications Mayer Davidson has written about Cost-Benefit Analysis.
Connection Strength
0.565
-
The "Cost-Effective" beneficial effect of pioglitazone on cardiovascular disease. Diabetes Res Clin Pract. 2020 07; 165:108223.
Score: 0.168
-
Rationale, design, and implementation of a cluster randomized trial using certified diabetes educators to intensify treatment for glycemia, blood pressure and lipid control: REMEDIES 4D. Contemp Clin Trials. 2014 Sep; 39(1):124-31.
Score: 0.112
-
The reality of type 2 diabetes prevention. Diabetes Care. 2014 Apr; 37(4):943-9.
Score: 0.109
-
Collaborative care for depression and chronic illnesses. N Engl J Med. 2011 03 31; 364(13):1278; author reply 1278-9.
Score: 0.089
-
Early insulin therapy for type 2 diabetic patients: more cost than benefit. Diabetes Care. 2005 Jan; 28(1):222-4.
Score: 0.058
-
Cost effectiveness of statin therapy for the primary prevention of major coronary events in individuals with type 2 diabetes. Diabetes Care. 2003 Jun; 26(6):1796-801.
Score: 0.013
-
Controlling blood glucose levels in patients with type 2 diabetes mellitus. An evidence-based policy statement by the American Academy of Family Physicians and American Diabetes Association. J Fam Pract. 2000 May; 49(5):453-60.
Score: 0.010
-
Cost-effective screening for diabetic retinopathy using a nonmydriatic retinal camera in a prepaid health-care setting. Diabetes Care. 1993 Aug; 16(8):1193-5.
Score: 0.007